MarginsXMarginsX
Home › Markets › Health Care › PFE

Pfizer Inc. (PFE)

PFE trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$28.86
-0.10% on the day
Market cap
$164.5B
Large cap
Revenue · 2025
$62.6B
-1.6% on 2024
Net income · 2025
$7.8B
12.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPFE on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000078003
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$62.6B
Net income$7.8B
Operating incomeNot in SEC XBRL data
Net margin12.4%
Operating marginOperating income not reported
Revenue growth-1.6%
Cash$1.1B
Total assets$208.2B
P/E (computed)21.2×
P/S (computed)2.6×

Warning signs

Cash runway
Cash-flow positive
$1.8B cash at September 27, 2026
Share count, 1 year
+0.2%
2025-10-29 to 2026-10-28 · +0.9% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
$2.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$1.8B cash; operating cash flow $3.5B a quarter.Report 2026-09-27
Shares outstanding5,699,853,733 (2026-10-28); 5,685,707,552 a year earlier; 5,646,413,292 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2025-11-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, New York, New York, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3.0M, sold $135K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-27
$16.6B$3.2B$5.4B$1.8B$62.6B$63.6B10-Q 2026-11-03
Q2 2026
2026-06-28
$15.0B-$248.0M$835.0M$976.0M$63.1B$63.7B10-Q 2026-08-04
Q1 2026
2026-03-29
$14.5B$2.7B$2.6B$1.7B$64.4B$63.3B10-Q 2026-05-05
Q4 2025
2025-12-31
$17.6B-$1.6B$5.3B$1.1B$64.6B$62.6B10-K 2026-02-26
Q3 2025
2025-09-28
$16.7B$3.5B$4.6B$1.3B$61.7B$62.8B10-Q 2026-11-03
Q2 2025
2025-06-29
$14.7B$2.9B-$582.0M$1.6B$61.7B$63.8B10-Q 2026-08-04
Q1 2025
2025-03-30
$13.7B$3.0B$2.3B$1.4B$61.4B$62.5B10-Q 2026-05-05
Q4 2024
2024-12-31
$17.8B$410.0M$6.7B$1.0B$61.2B$63.6B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52025-11-20
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-03-12

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.7%
1 month+1.8%
3 months+7.8%
Year to date+16.0%
1 year+12.0%
From 52-week high-6.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NVONovo Nordisk A/S$41.60-0.07%$184.2B
ABTAbbott Laboratories$107.45-0.99%$186.1B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
SNYSanofi ADS$48.39+0.04%$118.0B
GSKGSK plc$50.41-0.08%$102.0B
REGNRegeneron Pharmaceuticals Inc.$952.40-0.32%$98.5B
AZNAstraZeneca PLC$184.02-0.23%$285.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier